Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomePreferred Shares IssuedShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Cash from Financing Activities: 2013-2024

Historic Cash from Financing Activities for vTv Therapeutics (VTVT) over the last 12 years, with Dec 2024 value amounting to $52.6 million.

  • vTv Therapeutics' Cash from Financing Activities rose 3058.91% to $77.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $130.4 million, marking a year-over-year increase of 146.92%. This contributed to the annual value of $52.6 million for FY2024, which is 338.50% up from last year.
  • As of FY2024, vTv Therapeutics' Cash from Financing Activities stood at $52.6 million, which was up 338.50% from $12.0 million recorded in FY2023.
  • vTv Therapeutics' Cash from Financing Activities' 5-year high stood at $52.6 million during FY2024, with a 5-year trough of $12.0 million in FY2023.
  • In the last 3 years, vTv Therapeutics' Cash from Financing Activities had a median value of $14.8 million in 2022 and averaged $26.5 million.
  • As far as peak fluctuations go, vTv Therapeutics' Cash from Financing Activities plummeted by 45.31% in 2022, and later soared by 338.50% in 2024.
  • Yearly analysis of 5 years shows vTv Therapeutics' Cash from Financing Activities stood at $19.5 million in 2020, then surged by 38.55% to $27.0 million in 2021, then tumbled by 45.31% to $14.8 million in 2022, then declined by 18.69% to $12.0 million in 2023, then spiked by 338.50% to $52.6 million in 2024.